BioAge Labs Inc ( BIOA ) shares are up on Tuesday after the company reported positive Phase 1 data for BGE-102, an oral NLRP3 inhibitor.

Both the 120 mg and newly introduced 60 mg once-daily doses delivered significant median reductions in high-sensitivity C-reactive protein (hs-CRP), a key inflammation marker linked to cardiovascular disease risk.

The results are boosting investor sentiment toward the clinical-stage biotech, which is focused on developing treatments for metabolic diseases.

BioAge Labs Drug Shows Over 85% Reduction in Key Biomarker

BioAge Labs ( BIOA ) reported that BGE-102 achieved median hsCRP reductions of over 85% in participants with obesity and elevated baseline inflammation.

The company plans to initiate a Phase 2 proof-of-concept trial in cardiovascular risk in mid-2026. It expects results by the end of the year.

BioAge ( BIOA ) also plans to initiate a Phase 1b/2a proof-of-concept study. The mid-2026 process will evaluate BGE-102 in patients with diabetic macular edema (DME). It expects results in mid-2027.

Technical Analysis Signals Continued Bullish Trend

BioAge Labs ( BIOA ) is currently trading significantly above its 200-day simple moving average (SMA), which suggests robust long-term momentum. The stock is trading 13.6% above its 20-day SMA and 1.6% above its 50-day SMA. This indicates positive short-term strength.

The relative strength index (RSI) is at 55.14, suggesting that the stock is in neutral territory, with no immediate overbought or oversold conditions. This positioning indicates a balanced market sentiment among traders.

Key Resistance: $22.00 — A level where selling pressure may emerge.

Key Support: $18.50 — A level where buying interest could appear.

The stock has shown impressive performance over the past 12 months, returning 367.66%, reflecting strong investor interest and confidence in the company’s growth potential.

Currently, BioAge ( BIOA ) is trading near its 52-week high of $24.00, suggesting that it has been on an upward trajectory, reinforcing bullish sentiment.

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $51.50. Recent analyst moves include:

Needham: Initiated with Buy (Target $50.00) (March 27)

Citigroup: Buy (Raises Target to $52.00) (March 10)

Oppenheimer: Initiated with Outperform (Target $60.00) (February 25)

BIOA Stock Price Activity: BioAge Labs ( BIOA ) shares were up 0.13% at $18.82 on Tuesday, according to Benzinga Pro data.

Image via Shutterstock